Skip to main content
SALUDA MEDICAL, INC. logo

SALUDA MEDICAL, INC. — Investor Relations & Filings

Ticker · SLD ISIN · AU0000432114 ASX Manufacturing
Open in API
Filings indexed 38 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country AU Australia
Listing ASX SLD

About SALUDA MEDICAL, INC.

https://www.saludamedical.com

Saluda Medical, Inc. is a global medical device company focused on developing and commercializing advanced neuromodulation technologies for the treatment of chronic pain. The company’s flagship product, the Evoke® Spinal Cord Stimulation (SCS) System, is the first closed-loop SCS technology designed to measure the spinal cord's individual response to electrical stimulation using Evoked Compound Action Potentials (ECAPs). Unlike traditional open-loop systems that provide a fixed output, the Evoke System automatically adjusts stimulation levels in real-time to maintain consistent neural activation based on the patient's physiological needs and movements. This data-driven approach aims to optimize therapeutic outcomes and improve the long-term management of chronic pain through personalized, physiological feedback.

Recent filings

Filing Released Lang Actions
ASIC Approval of Financial Reporting Relief for Subsidiary 3 pages 138.4KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement notifying investors of ASIC’s grant of financial reporting relief for the company’s Australian subsidiary. It contains no actual financial statements or substantive financial data, and is not an operational report (e.g., 10-K, IR) but rather a regulatory update. It does not solicit votes nor report vote results, nor is it a call transcript or dividend notice. As a generic regulatory announcement, it falls under the “Regulatory Filings” category (RNS).
2026-05-14 English
Quarterly Activities/Appendix 4C Cash Flow Report 12 pages 529.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q3 FY26 Quarterly Activity Report and Appendix 4C' and provides detailed financial and operational data for the third quarter of fiscal year 2026. It includes revenue figures, growth percentages, operational updates, cash flow information, and guidance updates. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year indicates this is a quarterly report. The document is approximately 15,000 characters long, which is consistent with a full report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-29 English
Notification regarding unquoted securities - SLD 7 pages 20.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted equity securities under an employee incentive scheme by Saluda Medical, Inc. It includes specifics such as security codes, issue dates, quantities, and compliance with ASX Listing Rules. The content focuses on the issuance of securities and related regulatory disclosures rather than financial results, management changes, or other report types. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document length is 6452 characters, sufficient to contain substantive details of the issuance rather than a brief announcement or a report publication notice. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2026-04-09 English
Notification of cessation of securities - SLD 4 pages 15.3KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (expiry or lapse) of certain securities (options) for Saluda Medical, Inc. It includes specific data on the number of securities ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement to the ASX regarding changes in the company's issued securities, specifically the cessation of certain options. This type of document is a regulatory announcement about changes in securities status, not a financial report, earnings release, or management discussion. It fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 4569 characters, which is consistent with a detailed regulatory announcement rather than a brief report publication announcement or a full financial report.
2026-04-09 English
Half Yearly Report and Accounts 34 pages 1.6MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-Year Information For the six months ended December 31, 2025' and includes detailed financial statements such as condensed consolidated balance sheets, statements of operations and comprehensive loss, and cash flows for the six-month period ending December 31, 2025. It also includes a report of independent registered public accounting firm reviewing the interim financial information. The presence of unaudited interim financial statements and the reference to the six-month period clearly indicate this is a comprehensive interim or quarterly financial report. The document is about 15,000 characters long, which is consistent with a full interim report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-02-25 English
H1 FY2026 Results Announcement 6 pages 199.8KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 26 February 2026 reporting the half-year financial results (H1 FY26) of Saluda Medical, Inc. It includes detailed financial data such as revenue, gross margin, adjusted EBITDA, cash used in operations, and operational updates for the six-month period ended 31 December 2025. The document also contains forward-looking guidance for FY26 and references an investor webinar to discuss these results. The presence of comprehensive financial figures and analysis for a half-year period clearly identifies this as an Interim / Quarterly Report. The document length (13,692 characters) and detailed financial content confirm it is the report itself, not merely an announcement of a report publication. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2026-02-25 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.